[go: up one dir, main page]

WO1997038685A1 - Utilisation d'un osmolyte dans la preparation d'un medicament destine a traiter des complications resultant de l'ischemie - Google Patents

Utilisation d'un osmolyte dans la preparation d'un medicament destine a traiter des complications resultant de l'ischemie Download PDF

Info

Publication number
WO1997038685A1
WO1997038685A1 PCT/EP1997/001861 EP9701861W WO9738685A1 WO 1997038685 A1 WO1997038685 A1 WO 1997038685A1 EP 9701861 W EP9701861 W EP 9701861W WO 9738685 A1 WO9738685 A1 WO 9738685A1
Authority
WO
WIPO (PCT)
Prior art keywords
osmolyte
cells
use according
betaine
complications
Prior art date
Application number
PCT/EP1997/001861
Other languages
English (en)
Inventor
Dieter Häussinger
Original Assignee
Haeussinger Dieter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haeussinger Dieter filed Critical Haeussinger Dieter
Priority to JP9536745A priority Critical patent/JP2000508651A/ja
Priority to EP97919356A priority patent/EP0946167A1/fr
Priority to AU23860/97A priority patent/AU2386097A/en
Priority to US08/878,557 priority patent/US5880098A/en
Publication of WO1997038685A1 publication Critical patent/WO1997038685A1/fr
Priority to NO984759A priority patent/NO984759L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to the use of organic osmolytes in the manufacture of a therapeutic agent capable of treating or preventing complications resulting from ischemia, hypoxia or oxidative stress.
  • osmolytes In mammals, osmolytes have been identified in astrocytes, renal medulla cells and lens epithelia. The need for osmolytes in renal medulla cells is obvious, because ambient medullary osmolarity can increase up to 3800 mosmol/1 during antidiuresis and decrease to 170 mosmol/1 during diuresis. In the antidiuretic state (high extracellular osmolarity), intracellular osmolarity increases in renal medullary cells as the result of the intracellular accumulation of inositol and betaine which are taken up via sodium ion dependent transporters. These sodium ion dependent transporters are induced upon hyperosmotic exposure in renal cells and astrocytes.
  • Organ transplantation has become an established therapy for end stage liver and heart disease, although primary graft non-function or dysfunction is serious clinical problem.
  • Cold ischemic storage and the following reperfusion of the donated organ are identified as major contributors to failing primary graft function and is shown to have a detrimental impact on endothelial and immune competent cells, injuries to the endothelial cells precipitates a malfunction vascular system and consequently, an inadequate oxygen and substrate delivery, as well as an impaired waste product clearance.
  • the challenged endothelium enhances the expression of adhesive molecules facilitating the binding and infiltration of immune competent cells in the tissue area at risk.
  • Immune competent cells respond to ischemia and reperfusion by producing a number of biologically toxic mediators, again leading to the dysfunction of surrounding cells, including the vascular endothelium and in certain cases the whole organ.
  • the early organ dysfunction is considered to originate from injuries of endothelial cells resulting in inadequate oxygen and substrate delivery as well as reduced waste product clearance. Beyond transplantation injuries, resulting from ischemia and reperfusion, these are a well recognized clinical problems in, for example, myocardial infarction and the following thrombolytic treatment. As disclosed in Laboratory Investigation, 1996, Vol. 74, No. 1, p.
  • both myocardial ischemia and hypoxia can induce cell death , such as programmed cell death (apoptosis) in the heart following myocardial infarction which may lead to massive loss of cells and further organ damages.
  • cell death such as programmed cell death (apoptosis) in the heart following myocardial infarction which may lead to massive loss of cells and further organ damages.
  • apoptosis programmed cell death
  • the inflammatory response to ischemia and reperfusion is suggested to be primarily mediated by resident macrophages, the Kupffer cells, while the heart in such a situation suffers from invading immune competent cells which might cause persistent injuries.
  • oxidative stress In response to ischemia/reperfusion and inflammatory mediators, endothelial and immune competent cells produce oxygen free radicals which exert a detrimental metabolic load on exposed cells termed oxidative stress.
  • the oxidative stress precipitates severe damages to biological molecules, especially to DNA, lipids and proteins.
  • the protection against oxidative stress and hence the salvage of tissues and organs might be achieved only partially by supplying antioxidants and ensuring an adequate level of antioxidant enzymes. It would therefore also be desirable to be able to provide a therapy which also is useful for improving the protection of cells against damages originating from oxidative stress.
  • taurine possibly contributes to a regulation of the myocardial calcium uptake and thus may increase the myocardial activity.
  • certain osmolytes such as betaine and taurine, have a powerful capacity to maintain the cellular integrity in specific cells, and thereby the organ function, subjected to a depletion of oxygen in an anoxia model or oxidative stress, as demonstrated in an isolated, perfused liver.
  • the present invention shows that selected osmolytes can be employed as important regulators of endothelial and immune competent cell function.
  • the osmolytes have a capacity to protect these cell types or to affect such cells to modulate their response to the mentioned complications and thereby maintaining the function of vital organs challenged by pathologic events, such as an inadequate blood supply.
  • the failing liver is an early event in sepsis and accompanied by raised enzyme leakage from the liver, for example lactate dehydrogenase (LDH) which indicates a compromised cellular integrity.
  • LDH lactate dehydrogenase
  • As a sign of an adequate treatment the hepatic function and enzyme leakage is restored to near normal levels within days. This course of pathological events and the impact of a successful treatment, reflects the clinical importance of the marked decrease in LDH leakage in response to osmolyte treatment following anoxia, as will be described in the present invention.
  • the present invention demonstrates that otherwise metabolically inert osmolytes have a high potency in protecting organs or tissues from such damages and dysfunctions resulting from ischemia and reperfusion, hypoxia or oxidative stress.
  • the present invention is related to the use of an effective amount of an osmolyte in the preparation of a therapeutic agent capable treating or preventing complications resulting from ischemia, hypoxia or oxidative stress by affecting cells which produce mediators of such complications.
  • a therapeutic agent capable treating or preventing complications resulting from ischemia, hypoxia or oxidative stress by affecting cells which produce mediators of such complications.
  • Such cells may have an active part in the immune system and typically include, but are not strictly limited to, immune competent cells, endothelial cells and hepatocytes.
  • this type of cells are protected to maintain their regular metabolic function or are affected to modulate their response to the complications of ischemia, hypoxia and oxidative stress, in order to maintaining the function of vital organs challenged from pathologic events, such an inadequate blood supply.
  • ischemic or hypoxic conditions typically origin from a situation where the ordinary blood flow of substrates to an organ or a tissue is interrupted or reduced, so the regular metabolism is altered. Such situations can occur in connection to a large variety of traumatic events, such as myocardial infarction, bypass surgery of the heart or other organs or organ transplantation.
  • the present invention also serves as a cytoprotective therapy by increasing a correct cellular hydration in response to stress.
  • patients suffering from identified vascular dysfunctions such as those suffering from the effects or diabetes or who are expecting additional surgery or therapy can benefit from a therapy with selected osmolytes according to the present invention in connection with their regular therapy.
  • the osmolytes are defined as agents used by the cells to regulate the level of hydration by a specific transport mechanism through the cellular membranes. Such agents traditionally have been considered biologically inert, except for their function as substrates in metabolic pathways.
  • the osmolytes are defined as agents that are used in the regulation of the cellular hydration with the additional capacity to protect organs against injuries resulting from ischemia, hypoxia and oxidative stress.
  • osmolytes are useful for the preservation of the organ function at abnormal temperatures (hypothermia) induced during preservation prior to the transplantation
  • the osmolytes are preferably selected from a group consisting of polyols, amino acids and methylamines which are endogenously occurring in the body for regulating the individual cellular volume and osmolarity after exposure to osmotic variations and other stimuli related to the immune defense, as explained in our co-pending Swedish patent application 9601395-8
  • amino acid osmolytes methylamine osmolytes, such as taurine and betaine and certain polyols, such as myo-inositol
  • methylamine osmolytes such as taurine and betaine
  • certain polyols such as myo-inositol
  • the osmolytes can be administered as salts or as precursors, such as alkyl esters of osmolytes or osmolytes in ohgopeptides, capable of being released at their functional cellular target.
  • osmolytes can be administered when suitable, as is examphfied by a supplement of choline as a precursor to betaine
  • choline can be converted to betaine by hepatocytes for transport to the Kupffer cells of the liver where it may exert the mentioned effects Choline can however not be converted to betaine by the Kupffer cells.
  • the present invention it is possible to add one or several constituents capable of contributing to a prevention of the impairing effects resulting from the ischemic or hypoxic conditions
  • constituents capable of contributing to a prevention of the impairing effects resulting from the ischemic or hypoxic conditions
  • examples of such compounds are for example, found among certain amino acids, their precursors and derivatives, such as alpha-ketoglutarate as disclosed in WO 95/34301 (Pharmacia AB) which hereby is inco ⁇ orated as a reference.
  • An important aspect of the present invention is to use therapeutically effective amounts of an osmolyte and a thrombolytic agent in combination for the manufacture of an agent capable of treating complications resulting from ischemia, hypoxia or oxidative stress
  • an agent capable of treating complications resulting from ischemia, hypoxia or oxidative stress
  • Such an agent will be especially useful for treating complications in relation to myocardial infarction wherein the thrombolytic agent with a capacity to induce lysis of blood clots, or the procedure of percutaneous transluminal coronary angioplasty (PTCA) is combined with osmolytes to minimize the risk of coronary and vascular damages and restenosis.
  • PTCA percutaneous transluminal coronary angioplasty
  • the present invention is also related to a composition
  • a composition comprising an effective amount of the mentioned osmolytes for administration to an organ or a tissue being subjected, or at the risk of being subjected, to an insufficient supply of substrates necessary for maintaining the normal metabolic function together with a pharmacologically acceptable carrier.
  • Such compositions are especially suitable for being supplied to the heart in connection with its interruption from a regular blood flow for example for treating myocardial infarction, during coronary bypass surgery or transplantation.
  • Such compositions can further comp ⁇ se agents as inco ⁇ orated in conventional preservation solutions or cardioplegic agents, such as Plegisol® (Abbott Laboratories), St Thomas solution or the University of Wisconsin solution or other preservative agents or energy substrates as suggested in WO 95/34301.
  • compositions can preferably as mentioned be combined with a conventional thrombolytic agent, such as streptokinase
  • a conventional thrombolytic agent such as streptokinase
  • the thrombolytic agent can be added to the osmolytic composition, or administered separately in a predetermined manner.
  • inventive compositions can also be included in blood cardioplegia and in solutions useful as blood substitutes.
  • the compositions according to the present invention are also useful as solutions for the preservation of organs interrupted from their regular blood flow m combination with conventional preservative agents.
  • compositions for the treatment of patients suffering from diabetes or such post-traumatic patients dependent on an insulin therapy comprising an effective amount insulin in a conventional dosage form together with a therapeutically effective amount of at least one of the selected osmolytes, as mentioned above.
  • Such a composition can be in the form of an injectible preparation or an otherwise administerable dosage form of a conventional insulin in an effective amount, either directly mixed with osmolytes, or with the osmolyte preparation separately administerable in the as a part of kit, to be self administered by the patient in the connection with the insulin therapy
  • Effective amounts of the osmolytes in the inventive compositions shall, suitably after administration, provide between about 50 ⁇ M up to about 10 mM of osmolyte concentration in the fluid supplied to the organ or the tissue, preferably between a concentration of about 0 1 mM up to about 1-2 mM and most preferably about 0 5 mM
  • An especially effective composition has been shown to comp ⁇ se betaine and taurine at a total concentration of about 0 2 mM
  • Fig 1 shows an anoxic model on a perfused liver, wherein lactate dehydrogenase
  • LDH LDH in the effluent is used as a marker on cellular impairments is plotted against the perfusion time for control and the inco ⁇ oration of 0 1 mM and 1 mM of betaine in the perfusion solution of 385 mosm/1, respectively
  • Fig. 2 shows the effect of ambient osmolahty on mRNA levels for the betaine transporter (BGT-1 ), the taurine transporter (TAUT), the myo-inositol transporter (SMIT) and GAPDH in the rat liver endothelial cells. Changes in osmolahty were performed by appropriate addition/removal of sodium chloride. The mRNA levels were determined by Northern blot analysis
  • Fig 3 shows the time-dependent induction of BGT-1 (betaine transporting protein) and TAUT (taurine transporting protein) and SMIT (the myo-inositol transporter) mRNA- levels in rat Kupffer cells
  • BGT-1 betaine transporting protein
  • TAUT taurine transporting protein
  • SMIT the myo-inositol transporter
  • mRNA levels for BGT-1 , TAUT, SMIT and glyceraldehydephosphate dehydrogenase (GAPDH) as a standard were determined by Northern blot analysis
  • Fig 4 shows an anoxic model on perfused liver similar to the one shown in
  • Fig 1 wherein the LDH release is measured in the effluent after periusion with solutions of 385 mosmM enriched with 0 100 mM betaine, 0 100 mM betaine + 0 100 mM taurine
  • Fig 5 shows a similar anoxic model as in Fig 1 , wherein PGE2 (prostaglandin E2) levels are measured in the effluent du ⁇ ng anoxia and reperfusion with a 385 mosmM solution which has been provided with 0 100 mM betaine and 1 mM betaine, respectively Fig.
  • PGE2 prostaglandin E2
  • FIG. 6 shows a model for inducing oxidative stress, wherein a rat liver is exposed to a solution of 0.2 mM t-butylhydroperoxide (t-BOOH) and perfusion with a 305 mosmM solution without and with 1 mM betaine.
  • the protective effect of 1 mM betaine in the perfusate is determined as LDH release in the effluent.
  • Fig. 7A shows the modulation of the CD95 ligand mRNA expression (a mediator for apoptosis) in rat Kupffer cells in response to LPS challenge ( 1 ug/ml for 6h). In experiments shown in bars 1 and 2, the cells were not incubated with LPS.
  • Fig. 7B shows the same experiment as in Fig 7A performed with rat sinusoidal endothelial cells.
  • Fig. 8 shows the influence of betaine on the transporters for betaine and taurine
  • BGT-1 and TAUT inducible nitric oxide synthase mRNA levels in RAW 264.7 mouse macrophages during hyperosmolarity.
  • the macrophages were exposed to LPS (1 ⁇ g/ml) for 6 hours in the presence or absence of 0.1 or 5 mmol/1 betaine.
  • the mRNA levels of the transporters and iNOS were determined by Northern blot analysis.
  • Kupffer cells from male Wistar rats of 300-400 g body weight raised in the local institute for laboratory animals were isolated by collagenase-pronase perfusion and separated by a single Nycodenz gradient and centrifugal elutriation.
  • Cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS) for 48 h.
  • FCS heat-inactivated fetal calf serum
  • the experiments were performed during the following 24 h using Krebs-Henseleit hydrogen carbonate buffer (pH 7.4) containing 10 mM glucose and 1 % FCS.
  • Endothelial cells of male Wistar rats were isolated according to the collagenase- pronase method and centrifugal elutriation technique, as described for the Kupffer cells Isolated endothelial cells were incubated the first day for 4 hours in the appropriate culture medium adjusted to the desired osmolarity (205, 255, 305 or 405 mosmol/1) The cells were harvested following incubation and used for mRNA analysis The cell viability was routinely tested by determination of enzyme leakage, 4 hours of a hyperosmotic (405 mosm/1) or a hypoosmotic incubation was without effect on viability
  • Livers of Wistar rats were perfused in situ as described in Eur. J. Biochem , 1989, Vol 181 , p 709-716, in the physiological antegrade direction (from portal to hepatic vein) in an open recirculating system
  • the perfusion medium used was bicarbonate buffered Krebs-Henseleit saline medium (equlibrated with O2/CO2 95:5 by volume).
  • Anoxia was introduced by interrupting the supply oxygenated buffer
  • LDH lactate dehydrogenase
  • RNA from near-confluent culture plates of Kupffer cells and endothelial cells were isolated by using guanidinethiocyanate solution. RNA samples were electrophoresed in a 0.8% agarose/3% formaldehyde and then blotted onto Hybond-N nylon membranes with 20X SSC (3 M NaCl, 0.3 M sodium citrate). After brief rinsing with water and UV- crosslinking (Hoefer UV-crosslinker 500), the membranes were inspected under UV illumination to determine RNA integrity and location of the 28S and 18S rRNA bands.
  • 20X SSC 3 M NaCl, 0.3 M sodium citrate
  • Blots were then subjected to a 3 h-prehybridization at 43 jC in 50% deionized formamide, in sodium phosphate buffer (0.25 M, pH 7.2), containing 0.25 M NaCl, 1 mM EDTA, 100 mg/ml salmon sperm DNA and 7% SDS.
  • Hybridization was carried out in the same solution with approx. 106 cpm/ml ( ⁇ -32P)dCTP-labeled random primed BGT-1 , TAUT and GAPDH cDNA probes.
  • Membranes were washed three times in 2x SSC/0.1 % SDS and twice in sodium phosphate buffer (25 mM, pH 7.2)/EDTA (1 mM)/l % SDS. Blots were then exposed to Kodak AR X-omat film at 70 °C with intensifying screens and analysed with PDI densitometry scanning (Pharmacia, Freiburg, Germany).
  • hypoxia resulted m a marked increase in LDH release demonstrating a deteriorating cell and organ integrity and function.
  • the described cell and tissue damage was characterized by an early injury, evident during hypoxia challenge recognized by an escalating LDH release and a late injury when normoxia was reinstituted (reperfusion injury)
  • treatment with 0.1 mM and 1 mM betaine solution was determined to diminish or even abolish the injury during and following hypoxia.
  • Fig. 2 and Fig. 3 show that mRNA for the betaine transport protein, BGT- 1 , the taurine transport protein, TAUT and the myo-inositol transporter SMIT, were expressed both in endothelial cells and Kupffer cells.
  • Fig. 2 The endothelial cells were strongly dependent on ambient osmolarity (Fig. 2) which demonstrates that osmolytes are important components in the regulation of cellular function in both immune competent cells and the endothelial cells of the vasculature. Moreover, in endothelial cells TAUT tended to be more intensively expressed than BGT-1 in response to the 4 hours of exposure to hyperosmolarity. In Kupffer cells, there was a time dependent increase in BGT-1 and TAUT mRNA expression, see Fig. 3. These findings shows that the composition of osmolytes, used according to the present invention, can be tailored to optimize therapeutic efficacy with respect to a target cell type, as well as the timing of the therapeutic intervention.
  • Fig. 4 shows that a co-administration of taurine and betaine during anoxia leads to a reduced leakage of LDH from the Kupffer cells, when compared to a supplementation of betaine only, or a standard solution of 385 mosmM
  • a supplementation of osmolytes will consequently suppress the macrophage activity which can be triggered by an ischemic or hypoxic event which otherwise could lead to a rupture of vascular plaques leading to thrombosis and an even more serious organ or tissues damages resulting from occlusions of vessel lumens, see e.g. The Lancet, 1996, Vol. 347, pag. 305-306, P Weisberg et al.
  • Fig. 7A and 7B demonstrates the capacity of osmolytes in protection of apoptosis
  • Fig. 8 shows that osmolytes are effective in downregulating inducible nit ⁇ c oxide synthase (iNOS).
  • iNOS inducible nit ⁇ c oxide synthase
  • a supplementation of selected osmolytes, according to the present invention to patients identified as being at risk of acquiring life-threatening coronary syndromes of unstable angina and myocardial infarction, precipitated by the rupture of cardiovascular plaques will be of benefit, since such a therapy will selectively modulate the activity of macrophages on the plaques.
  • the inventive osmolyte therapy thus demonstrates a considerable potential for supplying to such at risk patients who expect complementary surgery or therapy
  • the present invention has contributing potential, in terms of treating, but also in preventing damages resulting from ischemia and subsequent reperfusion by a capacity in stabilizing vascular plaques
  • a further aspect of preventing life threatening coronary syndromes by the inventive osmolyte therapy concerns patients suffering from pathologically raised levels of circulating metabolites capable of exerting osmotic stress on the vasculature, exemplified by raised levels of circulating glucose in the diabetic state
  • endothelial cells subjected to osmotic stress express osmolyte transporting proteins and thereby susceptibility to osmolyte therapy for their normalization of their cellular hydration and function.
  • osmolytes have a potential in preventing vascular dysfunctions leading to impairments of the blood flow, vascular dysfunction and related diseases in the diabetic patient, for example by being administered in connection with conventional insulin therapy as a preventive therapy for cardiovascular or other vascular diseases in the diabetic state.
  • the beneficial effect of osmolytes on the tissue capacity for scavenging oxygen free radicals serves as a mechanistic basis for the described improvement of tolerance to oxidative stress as shown in Fig. 6 .
  • the extent of damages from oxidative stress, also resulting from reperfusion, can consequently be reduced therapy of supplying selected osmolytes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une thérapie impliquant l'utilisation de doses efficaces d'un osmolyte, par exemple la taurine, la bétaïne ou des inositols, lesquels peuvent traiter ou prévenir des complications résultant de l'ischémie, de l'hypoxie ou du stress consécutif à l'oxydation.
PCT/EP1997/001861 1996-04-12 1997-04-14 Utilisation d'un osmolyte dans la preparation d'un medicament destine a traiter des complications resultant de l'ischemie WO1997038685A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP9536745A JP2000508651A (ja) 1996-04-12 1997-04-14 虚血を原因とする合併症を治療する医薬を製造するためのオスモライトの使用
EP97919356A EP0946167A1 (fr) 1996-04-12 1997-04-14 Utilisation d'un osmolyte dans la preparation d'un medicament destine a traiter des complications resultant de l'ischemie
AU23860/97A AU2386097A (en) 1996-04-12 1997-04-14 Use of an osmolyte in the preparation of a medicament for treating complicati ons resulting from ischemia
US08/878,557 US5880098A (en) 1996-04-12 1997-06-19 Therapeutic treatment
NO984759A NO984759L (no) 1996-04-12 1998-10-12 Anvendelse av en osmolytt ved fremstilling av et medikament for behandling av komplikasjoner forÕrsaket av iskemi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9601396A SE9601396D0 (sv) 1996-04-12 1996-04-12 New therapeutic treatment 2
SE9601396-6 1996-04-12

Publications (1)

Publication Number Publication Date
WO1997038685A1 true WO1997038685A1 (fr) 1997-10-23

Family

ID=20402175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/001861 WO1997038685A1 (fr) 1996-04-12 1997-04-14 Utilisation d'un osmolyte dans la preparation d'un medicament destine a traiter des complications resultant de l'ischemie

Country Status (7)

Country Link
EP (1) EP0946167A1 (fr)
JP (1) JP2000508651A (fr)
AU (1) AU2386097A (fr)
CA (1) CA2251071A1 (fr)
NO (1) NO984759L (fr)
SE (1) SE9601396D0 (fr)
WO (1) WO1997038685A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
WO2000051596A1 (fr) * 1999-03-02 2000-09-08 Jallal Messadek La glycine betaïne pour son usage antithrombotique
WO2000076528A3 (fr) * 1999-06-12 2001-09-07 Bitop Gmbh Preparation pharmaceutique
WO2001076572A3 (fr) * 2000-04-12 2002-04-11 Bitop Gmbh Utilisation de solutes compatibles en tant que substances aux proprietes de piegeage de radicaux
RU2259822C1 (ru) * 2004-02-27 2005-09-10 ЗАО "НПО ПЦ Биофизика" Противоишемическое средство, обладающее противоаритмическим и противоатерогенным действием, и способ его применения
WO2006050585A3 (fr) * 2004-11-10 2007-03-22 Jallal Messadek Modulation de synthases d'oxyde nitrique par des betaines
DE102008006780A1 (de) * 2008-01-30 2009-08-06 Bitop Ag Verwendung von Tetrahydropyrimidinen
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
US7780990B2 (en) 2005-02-15 2010-08-24 Jallal Messadek Combination therapeutic compositions and method of use
US7786077B2 (en) 2005-04-27 2010-08-31 Jallal Messadek Insulins combinations
US8343947B2 (en) 2003-07-15 2013-01-01 Jallal Messadek Therapeutic treatment

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5084089B2 (ja) * 2001-06-14 2012-11-28 大塚製薬株式会社 医薬組成物
DE10330768A1 (de) * 2003-07-07 2005-02-24 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung
JP2021147393A (ja) * 2020-03-13 2021-09-27 ロート製薬株式会社 酸化ストレス抑制剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359257A2 (fr) * 1988-09-15 1990-03-21 Perstorp Ab Utilisation du triphosphate d'inositol pour préparer un médicament contre le diabète
JPH0381219A (ja) * 1989-08-24 1991-04-05 Motoyasu Murakami 胃粘膜障害治療剤
WO1991009601A1 (fr) * 1989-12-21 1991-07-11 Perstorp Ab Utilisation de phosphates d'inositol pour la preparation d'un medicament
WO1991014435A1 (fr) * 1990-03-19 1991-10-03 Brigham And Women's Hospital Traitement de troubles osmotiques a l'aide d'osmolytes organiques
WO1992015546A1 (fr) * 1991-03-05 1992-09-17 The Regents Of The University Of California Composes et procede de protection de cellules et de tissus contre des lesions irreversibles dues a l'acidose lactique
DE4331711A1 (de) * 1992-09-18 1994-03-24 Pasteur Merieux Serums Vacc Lösung zur Perfusion, Konservierung und Re-Perfusion von Organen
WO1996032906A1 (fr) * 1995-04-18 1996-10-24 Nutrition 21 Taurate de magnesium utilise a des fins therapeutiques

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359257A2 (fr) * 1988-09-15 1990-03-21 Perstorp Ab Utilisation du triphosphate d'inositol pour préparer un médicament contre le diabète
JPH0381219A (ja) * 1989-08-24 1991-04-05 Motoyasu Murakami 胃粘膜障害治療剤
WO1991009601A1 (fr) * 1989-12-21 1991-07-11 Perstorp Ab Utilisation de phosphates d'inositol pour la preparation d'un medicament
WO1991014435A1 (fr) * 1990-03-19 1991-10-03 Brigham And Women's Hospital Traitement de troubles osmotiques a l'aide d'osmolytes organiques
WO1992015546A1 (fr) * 1991-03-05 1992-09-17 The Regents Of The University Of California Composes et procede de protection de cellules et de tissus contre des lesions irreversibles dues a l'acidose lactique
DE4331711A1 (de) * 1992-09-18 1994-03-24 Pasteur Merieux Serums Vacc Lösung zur Perfusion, Konservierung und Re-Perfusion von Organen
WO1996032906A1 (fr) * 1995-04-18 1996-10-24 Nutrition 21 Taurate de magnesium utilise a des fins therapeutiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANAS, P.E.: "The Role of Taurine and its Derivatives on Cellular Hypoxia: A Physiological View", ACTA PHYSIOL. PHARMACOL. THER. LATINOAM. (ARGENTINA), vol. 42, no. 3, 1992, pages 133 - 137, XP002037363 *
MINOR T. ET AL: "Taurine Reduces Experimental Liver Injury After Cold Ischemic Preservation and a Period of Rewarming Prior to Reperfusion", ADV. EXP. MED. BIOL. (UNITED STATES), vol. 403, 1996, pages 157 - 161, XP002037362 *
RAO P.S. ET AL: "Protection of Ischemiac Heart from Reperfusion Injury by Myo-Inositol Hexaphosphate, a Natural Antioxidant", ANN. THORAC. SURG. (UNITED STATES), vol. 52, no. 4, 1991, pages 908 - 912, XP002037360 *
WINGENFELD P. ET AL: "Protecting Effect of Taurine against Hypoxic Cell Damge in Renal Tubular Cells Cultured in Different Transplant Preservation Solutions", ADV. EXP. MED. BIOL. (USA), vol. 359, 1994, pages 159 - 169, XP002037361 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
WO2000051596A1 (fr) * 1999-03-02 2000-09-08 Jallal Messadek La glycine betaïne pour son usage antithrombotique
BE1012495A3 (fr) * 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
JP2002538113A (ja) * 1999-03-02 2002-11-12 メッサデク ジャラル 抗血栓剤用途へのグリシンベタインの使用
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
US6855734B2 (en) 1999-03-02 2005-02-15 Jallal Messadek Glycine betaine and its use
US7147849B2 (en) 1999-06-12 2006-12-12 Bitop Ag Pharmaceutical formulation
WO2000076528A3 (fr) * 1999-06-12 2001-09-07 Bitop Gmbh Preparation pharmaceutique
WO2001076572A3 (fr) * 2000-04-12 2002-04-11 Bitop Gmbh Utilisation de solutes compatibles en tant que substances aux proprietes de piegeage de radicaux
JP2003531833A (ja) * 2000-04-12 2003-10-28 ビトプ アクチェンゲゼルシャフト フューア ビオテヒニシェ オプティミールング フリーラジカル捕捉特性を有する物質としての適合溶質の使用
US8343947B2 (en) 2003-07-15 2013-01-01 Jallal Messadek Therapeutic treatment
RU2259822C1 (ru) * 2004-02-27 2005-09-10 ЗАО "НПО ПЦ Биофизика" Противоишемическое средство, обладающее противоаритмическим и противоатерогенным действием, и способ его применения
WO2006050585A3 (fr) * 2004-11-10 2007-03-22 Jallal Messadek Modulation de synthases d'oxyde nitrique par des betaines
US8318805B2 (en) 2004-11-10 2012-11-27 Jallal Messadek Modulation of nitric oxide synthases by betaines
US7780990B2 (en) 2005-02-15 2010-08-24 Jallal Messadek Combination therapeutic compositions and method of use
US7786077B2 (en) 2005-04-27 2010-08-31 Jallal Messadek Insulins combinations
DE102008006780A1 (de) * 2008-01-30 2009-08-06 Bitop Ag Verwendung von Tetrahydropyrimidinen

Also Published As

Publication number Publication date
SE9601396D0 (sv) 1996-04-12
AU2386097A (en) 1997-11-07
EP0946167A1 (fr) 1999-10-06
JP2000508651A (ja) 2000-07-11
CA2251071A1 (fr) 1997-10-23
NO984759D0 (no) 1998-10-12
NO984759L (no) 1998-10-12

Similar Documents

Publication Publication Date Title
US5880098A (en) Therapeutic treatment
Hoffman et al. Myocardial reperfusion injury: etiology, mechanisms, and therapies
Wang et al. Effect of vitamin E against adriamycin-induced toxicity in rabbits
EP0464084B1 (fr) Emploi d'acide eicosapentaeno que dans le traitement de la cachexie
Buehler et al. Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig
Powers et al. Twenty-five percent albumin prevents lung injury following shock/resuscitation
Bolcal et al. Protective effects of antioxidant medications on limb ischemia reperfusion injury
EP0946167A1 (fr) Utilisation d'un osmolyte dans la preparation d'un medicament destine a traiter des complications resultant de l'ischemie
US5457130A (en) Eicosapentaenoic acid used to treat cachexia
Chen et al. Type 2 diabetic mellitus related osteoporosis: focusing on ferroptosis
Mavier et al. Human monocyte-mediated tumor cytotoxicity. I. Demonstration of an oxygen-dependent myeloperoxidase-independent mechanism.
US5843996A (en) Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution
Ikeda et al. Liver graft exposure to carbon monoxide during cold storage protects sinusoidal endothelial cells and ameliorates reperfusion injury in rats
US20120041006A1 (en) Compositions for Raising Uric Acid Levels and Methods of Using the Same
Ishizaki et al. COMPARISON OF VARIOUS LAZAROID COMPOUNDS FOR PROTECTION AGAINST ISCHEMIC LIVER INJURY1, 2
Bezinover et al. Use of a third-generation perfluorocarbon for preservation of rat DCD liver grafts
Mikrut et al. The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia
WO1997038686A1 (fr) Utilisation d'un osmolyte pour traiter les effets d'une infection, d'une inflammation ou d'une dysfonction du systeme immunitaire
CN115414344A (zh) L-瓜氨酸在制备防治铁过载药物中的应用
JP4709552B2 (ja) Ｌｆａ−１抑制剤、及びその用途
Wu et al. Reactive oxygen species in reoxygenation injury of rat brain capillary endothelial cells
Deng et al. Myocardial ischemia/reperfusion injury: mechanism and targeted treatment for ferroptosis
Peng et al. β‐Carotene exhibits antioxidant and anti‐apoptotic properties to prevent ethanol‐induced cytotoxicity in isolated rat hepatocytes
Gerlach et al. Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin
Goel et al. Herbicides poisoning: Paraquat and diquat

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 332069

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1997919356

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2251071

Country of ref document: CA

Ref country code: CA

Ref document number: 2251071

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997919356

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997919356

Country of ref document: EP